MA38346A3 - 2,3-benzodiazépines bicyclo- et spirocyclosubstituées - Google Patents
2,3-benzodiazépines bicyclo- et spirocyclosubstituéesInfo
- Publication number
- MA38346A3 MA38346A3 MA38346A MA38346A MA38346A3 MA 38346 A3 MA38346 A3 MA 38346A3 MA 38346 A MA38346 A MA 38346A MA 38346 A MA38346 A MA 38346A MA 38346 A3 MA38346 A3 MA 38346A3
- Authority
- MA
- Morocco
- Prior art keywords
- diseases
- spirocyclosubstituted
- benzodiazepines
- bicyclo
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D245/06—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
L'invention concerne des 2,3-benzodiazépines bicyclo- et spirocyclosubstituées à effet inhibiteur de protéine bet, en particulier à effet inhibiteur de brd4 de la formule générale (i), des principes pharmaceutiques contenant les composés selon l'invention, ainsi que leur utilisation prophylactique et thérapeutique contre les affections hyperprolifératives, en particulier contre les affections tumorales. En outre, l'invention concerne l'utilisation d'inhibiteurs de protéine bet en cas d'hyperplasie bénigne, d'affections athérosclérotiques, de septicémie, d'affections auto-immunes, d'affections vasculaires, d'infections virales, dans des affections neurodégénératives, dans des affections inflammatoires, dans des affections athérosclérotiques et dans le contrôle de fertilité masculine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102013202678 | 2013-02-19 | ||
PCT/EP2014/052984 WO2014128067A1 (fr) | 2013-02-19 | 2014-02-17 | 2,3-benzodiazépines bicyclo- et spirocyclosubstituées |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38346A3 true MA38346A3 (fr) | 2019-03-29 |
MA38346B1 MA38346B1 (fr) | 2019-05-31 |
Family
ID=50112918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38346A MA38346B1 (fr) | 2013-02-19 | 2014-02-17 | 2,3-benzodiazépines bicyclo- et spirocyclosubstituées |
Country Status (18)
Country | Link |
---|---|
US (1) | US20160129011A1 (fr) |
EP (1) | EP2958909A1 (fr) |
JP (1) | JP2016511247A (fr) |
KR (1) | KR20150119926A (fr) |
CN (1) | CN105263919A (fr) |
AP (1) | AP2015008673A0 (fr) |
AU (1) | AU2014220838A1 (fr) |
BR (1) | BR112015019811A2 (fr) |
CA (1) | CA2901352A1 (fr) |
CR (1) | CR20150426A (fr) |
DO (1) | DOP2015000200A (fr) |
HK (1) | HK1214819A1 (fr) |
IL (1) | IL240434A0 (fr) |
MA (1) | MA38346B1 (fr) |
PH (1) | PH12015501822A1 (fr) |
SG (1) | SG11201505979UA (fr) |
TN (1) | TN2015000354A1 (fr) |
WO (1) | WO2014128067A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6930913B2 (ja) | 2014-10-14 | 2021-09-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | 炎症を阻害するためのcdk9及びbrd4阻害剤の使用法 |
WO2016062688A1 (fr) * | 2014-10-23 | 2016-04-28 | Bayer Pharma Aktiengesellschaft | Dérivés de 1-phényl-4,5-dihydro-3h-2,3-benzodiazépines |
GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
JP6764877B2 (ja) * | 2015-03-30 | 2020-10-07 | ジュビラント バイオシス リミテッドJubilant Biosys Limited | がん治療に有用な1−(シクロ)アルキルピリジン−2−オンの三環式縮合誘導体 |
WO2017063959A1 (fr) * | 2015-10-15 | 2017-04-20 | Bayer Pharma Aktiengesellschaft | Dérivés de la benzodiazépine n-sulfoximinophényl-substitués utilisés comme inhibiteurs de protéines bet |
PL3416962T3 (pl) * | 2016-02-15 | 2021-11-22 | Sanofi | Pochodne 6,7-dihydro-5H-benzo[7]annulenu jako modulatory receptorów estrogenowych |
DE102017005091A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one |
DE102017005089A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one |
CA3152923A1 (fr) | 2019-09-30 | 2021-04-08 | Keisuke Yamamoto | Agent de degradation de bet |
WO2021152113A1 (fr) | 2020-01-31 | 2021-08-05 | Bayer Aktiengesellschaft | Dérivés de 2,3-benzodiazépines substitués |
CN112979658B (zh) * | 2021-02-22 | 2022-05-31 | 南湖实验室 | 一种氟马西尼的制备方法 |
CN113461700B (zh) * | 2021-03-31 | 2022-05-13 | 青岛农业大学 | 一种氧气促进的去芳香化反应在构建螺环二烯酮骨架中的应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU208429B (en) | 1991-05-03 | 1993-10-28 | Gyogyszerkutato Intezet | Process for producing 1-/3-chloro-phenyl/-4-methyl-7,8-dimethoxy-5h-2,3-benzodiazepine of high purity |
EP0703222A1 (fr) | 1993-05-13 | 1996-03-27 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de 3-aminoazepine et son utilisation pharmaceutique |
DE19604920A1 (de) | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
US5891871A (en) | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
EP1296960A2 (fr) * | 2000-06-16 | 2003-04-02 | Annovis, Inc. | Antagonistes 5h-2,3-benzodiazepine de recepteurs d'acide amine excitateurs |
GB0425196D0 (en) | 2004-11-15 | 2004-12-15 | Black James Foundation | Gastrin and cholecystokinin receptor ligands |
TW200902024A (en) | 2007-04-02 | 2009-01-16 | Teva Pharma | Novel 2,3-benzodiazepine derivatives and their use as antipsychotic agents |
CN101910182B (zh) | 2007-12-28 | 2013-07-17 | 田边三菱制药株式会社 | 抗癌剂 |
GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
BR112012029005A2 (pt) | 2010-05-14 | 2016-07-26 | Dana Farber Cancer Inst Inc | composições e métodos de tratamento de neoplasia, doença inflamatória e outros distúrbios |
WO2012075456A1 (fr) * | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Inhibiteurs de bromodomaines et leurs utilisations |
AR084070A1 (es) * | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
WO2013155695A1 (fr) | 2012-04-20 | 2013-10-24 | Abbott Laboratories | Dérivés d'iso-indolone |
US9624244B2 (en) | 2012-06-06 | 2017-04-18 | Constellation Pharmaceuticals, Inc. | Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof |
TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
CA2874953A1 (fr) | 2012-06-12 | 2013-12-19 | Abbvie Inc. | Derives de pyridinone et de pyridazinone |
WO2014026997A1 (fr) * | 2012-08-16 | 2014-02-20 | Bayer Pharma Aktiengesellschaft | 2,3-benzodiazépines |
-
2014
- 2014-02-17 WO PCT/EP2014/052984 patent/WO2014128067A1/fr active Application Filing
- 2014-02-17 CN CN201480022272.XA patent/CN105263919A/zh active Pending
- 2014-02-17 JP JP2015557453A patent/JP2016511247A/ja active Pending
- 2014-02-17 EP EP14704594.2A patent/EP2958909A1/fr not_active Withdrawn
- 2014-02-17 AP AP2015008673A patent/AP2015008673A0/xx unknown
- 2014-02-17 SG SG11201505979UA patent/SG11201505979UA/en unknown
- 2014-02-17 US US14/772,761 patent/US20160129011A1/en not_active Abandoned
- 2014-02-17 AU AU2014220838A patent/AU2014220838A1/en not_active Abandoned
- 2014-02-17 KR KR1020157025482A patent/KR20150119926A/ko not_active Application Discontinuation
- 2014-02-17 CA CA2901352A patent/CA2901352A1/fr not_active Abandoned
- 2014-02-17 MA MA38346A patent/MA38346B1/fr unknown
- 2014-02-17 BR BR112015019811A patent/BR112015019811A2/pt not_active IP Right Cessation
-
2015
- 2015-08-09 IL IL240434A patent/IL240434A0/en unknown
- 2015-08-18 TN TN2015000354A patent/TN2015000354A1/en unknown
- 2015-08-18 PH PH12015501822A patent/PH12015501822A1/en unknown
- 2015-08-19 CR CR20150426A patent/CR20150426A/es unknown
- 2015-08-19 DO DO2015000200A patent/DOP2015000200A/es unknown
-
2016
- 2016-03-10 HK HK16102753.5A patent/HK1214819A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CR20150426A (es) | 2015-10-20 |
AU2014220838A1 (en) | 2015-09-10 |
TN2015000354A1 (en) | 2017-01-03 |
WO2014128067A1 (fr) | 2014-08-28 |
US20160129011A1 (en) | 2016-05-12 |
HK1214819A1 (zh) | 2016-08-05 |
CA2901352A1 (fr) | 2014-08-28 |
IL240434A0 (en) | 2015-09-24 |
MA38346B1 (fr) | 2019-05-31 |
KR20150119926A (ko) | 2015-10-26 |
BR112015019811A2 (pt) | 2017-07-18 |
PH12015501822A1 (en) | 2015-12-07 |
CN105263919A (zh) | 2016-01-20 |
AP2015008673A0 (en) | 2015-08-31 |
EP2958909A1 (fr) | 2015-12-30 |
JP2016511247A (ja) | 2016-04-14 |
DOP2015000200A (es) | 2015-11-30 |
SG11201505979UA (en) | 2015-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38346B1 (fr) | 2,3-benzodiazépines bicyclo- et spirocyclosubstituées | |
MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
NZ722326A (en) | Tricyclic compounds as anticancer agents | |
MA35459B1 (fr) | Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit | |
BR112018074621A2 (pt) | derivados de pirazolopirimidina como inibidores de quinase | |
MX2020004183A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
MA40123A1 (fr) | Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia | |
MA46337B1 (fr) | Composé de pyridine | |
BR112014019052A8 (pt) | Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer | |
BR112015022391A8 (pt) | inibidores de domínio bromo tetracíclico | |
UA111272C2 (uk) | Конденсовані піримідинові похідні для інгібування тирозинкіназної активності | |
TN2014000420A1 (fr) | Derives d'indole et d'indazole qui activent la mpk | |
WO2014031928A3 (fr) | Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies | |
BR112015022551A2 (pt) | inibidores de amido pirrol | |
BR112015027951A8 (pt) | arilquinazolinas, seus usos, medicamento, composição farmacêutica, e kit | |
MA38039A1 (fr) | Composés de céphem substitués en position 2 | |
MA44948A1 (fr) | Inhibiteurs de bace 1 | |
WO2014031933A3 (fr) | Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies | |
MA43409B1 (fr) | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
GEP20207172B (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
WO2014031936A3 (fr) | Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies | |
MA38925A1 (fr) | Dérivés de phénylalanine substitués | |
EP2578590A4 (fr) | Composé anti-inflammatoire ayant une activité inhibitrice contre des tyrosine kinases multiples, et composition pharmaceutique contenant celui-ci | |
MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
AU2013208104A8 (en) | Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof |